Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

56.44
Delayed Data
As of Feb 24
 +0.67 / +1.20%
Today’s Change
46.01
Today|||52-Week Range
77.12
-3.42%
Year-to-Date
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, No...
Feb 24 / Zacks.com - Paid Partner Content
Icahn Takes Activist Stake In Bristol-Myers, Bets On $90 Billion Takeover
Feb 21 / Investing Channel - Paid Partner Content
Searle & Co. Buys Exxon Mobil, Bristol-Myers Squibb Company, Bank of Americaoration
Feb 24 / GuruFocus News - Paid Partner Content
Icahn Purchases Stake in Bristol-Myers
Feb 21 / TheStreet.com - Paid Partner Content
Company News for February 23, 2017
Feb 23 / Zacks.com - Paid Partner Content
Takeaways and Observations
Feb 21 / TheStreet.com - Paid Partner Content
Cramer: Buyers for Bristol-Myers Are Few and Far Between
Feb 22 / TheStreet.com - Paid Partner Content
Bristol-Meyers Adds Three New Directors
Feb 21 / TheStreet.com - Paid Partner Content
Who Could Buy Bristol-Myers Squibb?
Feb 22 / MotleyFool.com - Paid Partner Content
Factor Xa's Win Billions of Dollars in Sales From Warfarin
Feb 21 / MotleyFool.com - Paid Partner Content
Bristol Myers' Future Unsure as Carl Icahn Takes Stake
Feb 22 / Zacks.com - Paid Partner Content
Tiffany agrees board shake-up after activist pressure
Feb 21 / FT.com - Paid Partner Content
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
Feb 22 / Zacks.com - Paid Partner Content
Factor Xa's Win Billions of Dollars in Sales From Warfarin
Feb 21 / MotleyFool.com - Paid Partner Content
Bristol-Myers Squibb: grave dancing denied
Feb 22 / FT.com - Paid Partner Content
Your Burning Biotech Questions Answered
Feb 20 / TheStreet.com - Paid Partner Content
S&P 500 Trades Lower as Fed Signals Move on Rates 'Fairly Soon'
Feb 22 / TheStreet.com - Paid Partner Content
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
Feb 17 / Zacks.com - Paid Partner Content
Dow Turns Positive in Wishy-Washy Trading Ahead of Fed Minutes
Feb 22 / TheStreet.com - Paid Partner Content
How Bristol-Myers Squibb and Pfizer Are Winning a Big Brawl in Blood Thinners
Feb 16 / MotleyFool.com - Paid Partner Content
Heart-Thumping, Game-Changing Ways We're Treating Cardiovascular Disease
Feb 22 / MotleyFool.com - Paid Partner Content
3 Stocks We're Watching in the First Quarter
Feb 14 / MotleyFool.com - Paid Partner Content
Frontrunning: February 22
Feb 22 / Investing Channel - Paid Partner Content
Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb
Feb 13 / MotleyFool.com - Paid Partner Content
Stock Futures Creep Lower as Wall Street Awaits Clarity From the Fed
Feb 22 / TheStreet.com - Paid Partner Content
Brakes on the pathway to treating cancer
Feb 09 / FT.com - Paid Partner Content
Can Carl Icahn Save Bristol Myers Squibb?
Feb 21 / Zacks.com - Paid Partner Content
Merck hails rise in patient tests for immunotherapy drug Keytruda
Feb 02 / FT.com - Paid Partner Content